UPDATE: H.C. Wainwright Starts AmpliPhi Biosciences (APHB) at Buy

August 28, 2017 7:12 AM EDT
Get Alerts APHB Hot Sheet
Price: $0.32 --0%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 19 | Down: 8 | New: 28
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - August 28, 2017 7:19 AM EDT)

(updated to add analyst comment)

H.C. Wainwright initiates coverage on AmpliPhi Biosciences (NYSE: APHB) with a Buy rating and a price target of $5.00.

Analyst Joseph Pantginis notes the company is developing bacteriophage (phage) therapy to treat bacterial infections as the world increasingly continues to face multi-drug resistant strains, including the so called superbugs.

He notes many governmental, regulatory, and scientific initiatives are underway to failings of current antibiotics. He sees AmpliPhi is in the pole position to answer the call.

For an analyst ratings summary and ratings history on AmpliPhi Biosciences click here. For more ratings news on AmpliPhi Biosciences click here.

Shares of AmpliPhi Biosciences closed at $0.78 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot New Coverage, New Coverage

Related Entities

H.C. Wainwright